HCA Healthcare Inc

HCA Healthcare is a holding company. Through its subsidiaries, partnerships and joint ventures, the company owns and operates hospitals and related health care entities. Most of the company's general, acute care hospitals provide medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services and emergency services. The general, acute care hospitals also provide outpatient services such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology and physical therapy. The company's psychiatric hospitals provide therapeutic programs including child, adolescent and adult psychiatric care, adolescent and adult alcohol and drug abuse treatment and counseling.
  • TickerHCA
  • ISINUS40412C1018
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

HCA HEALTHCARE sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of HCA HEALTHCARE (US), a company active in the Health Care Providers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date May 4, 2021, the closing price was USD 206.34 and its potential was estimated at USD 226.52.

HCA Healthcare Inc: 1 director

A director at HCA Healthcare Inc sold/sold after exercising options 18,664 shares at 201.532USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under ...

HCA Healthcare, Inc. - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Valens Research

HCA - Embedded Expectations Analysis - 2021 03 17

HCA Healthcare, Inc. (HCA:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 17.9x Uniform P/E, implying bearish expectations for the firm. However, given management's confidence about capital project returns, technology initiative yields, and leverage reduction, markets are overly pessimistic and equity upside is likely Specifically, management is confident they can lower their leverage ratio, that their technology and scale initiatives will yield value over time, and that they can achieve a high percentage of their expected returns on their cap...

Valens Research

HCA - Valens Credit Report - 2021 03 09

CDS markets are slightly overstating credit risk with a CDS of 115bps relative to an Intrinsic CDS of 72bps, while cash bond markets are overstating credit risk with a cash bond YTW of 2.332% relative to an Intrinsic YTW of 1.452%. Meanwhile, Moody's is overstating HCA's fundamental credit risk with its Ba1 rating two notches lower than Valens' IG4 (Baa2) rating Incentives Dictate Behavior™ analysis highlights mostly positive signals for credit holders. HCA's compensation framework should drive management to focus on top-line growth and margin expansion. Moreover, management members are signi...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Equities Testing Support Coronavirus concerns are reverberating throughout markets, and there is no way to know for certain how serious things will get -- or how much further markets could sell off as a result. What we can say is our weight of the evidence approach suggests this is a contained pullback for now, and that several areas of the market are testing key support. This suggests the potential for a bounce at current levels. At the same time, in light of steep uptrend breakdowns for extended leadership areas (Nasdaq, S&P 500, Technology, AAPL, large-cap growth) stemming from yesterday's...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Examining Prior Extended Periods Despite our concerns regarding the growing performance disparity between the haves (e.g., Technology, FAANG, mega-caps, growth) and the have nots (e.g., Materials, Energy, small-caps, value), the silver lining continues to be that the latter group is not breaking down on an absolute (price) basis. Due to this fact along with several observations highlighted below, we remain bullish. Continue to buy the dips. • Sector Relative Strength Rankings & Weighting Recommendations. Cap-weighted growth Sectors Technology, Services, Discretionary, and Communications co...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Taking A Breather As the broad market takes a breather, the weight of the evidence continues to support our belief that we are in the early stages of a broad-based advance. As long as there are no significant negative market developments, a buy-the-dip mentality is warranted. Of course, the potential for a US-China tariff escalation remains a risk for the market, though that is likely to be the case for the foreseeable future. • Sector Relative Strength Rankings (RSR) & Weighting Recommendations. Health Care, Technology, and Manufacturing round out our top three cap-weighted Sectors in ter...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weigh...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Financial Sector names are at or near bullish price and RS inflections. (ex. WFC, ABCB, SNV, STL, NFBK, FII, and COF) • Many Healthcare Sector names are showing leadership characteristics. (ZBH, CUTR, UHS, HCA, CHE, AMED, WST, and NEOG) • Many IT service related names remain bullish. (ex. FISV, EBOV, GPN, TSS, and EXLS)

HCA Healthcare Inc: 1 director

A director at HCA Healthcare Inc sold/sold after exercising options 18,664 shares at 201.532USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under ...

Valens Research

HCA - Embedded Expectations Analysis - 2021 03 17

HCA Healthcare, Inc. (HCA:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 17.9x Uniform P/E, implying bearish expectations for the firm. However, given management's confidence about capital project returns, technology initiative yields, and leverage reduction, markets are overly pessimistic and equity upside is likely Specifically, management is confident they can lower their leverage ratio, that their technology and scale initiatives will yield value over time, and that they can achieve a high percentage of their expected returns on their cap...

Valens Research

HCA - Valens Credit Report - 2021 03 09

CDS markets are slightly overstating credit risk with a CDS of 115bps relative to an Intrinsic CDS of 72bps, while cash bond markets are overstating credit risk with a cash bond YTW of 2.332% relative to an Intrinsic YTW of 1.452%. Meanwhile, Moody's is overstating HCA's fundamental credit risk with its Ba1 rating two notches lower than Valens' IG4 (Baa2) rating Incentives Dictate Behavior™ analysis highlights mostly positive signals for credit holders. HCA's compensation framework should drive management to focus on top-line growth and margin expansion. Moreover, management members are signi...

Valens Research

Valens Credit Weekly Insights - 2021 02 24

Valens Credit Research Team highlighted ideas for DRI, GPS, and WBT. They have also provided recent analyses for BBY and IBP, while RIG topped the quantitative outlier report for the week.

Valens Research

Valens Credit Weekly Insights - 2021 02 17

Valens Credit Research Team highlighted ideas for AXL, TPR, and UAA. They have also provided recent analyses for GHC, while RIG topped the quantitative outlier report for the week.

Valens Research

Valens Credit Weekly Insights - 2021 02 10

Valens Credit Research Team highlighted ideas for MAT, KTOS, and VREX. They have also provided recent analyses for TRIP and CNC, while RIG topped the quantitative outlier report for the week.

HCA Healthcare, Inc. - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's: HCA Healthcare's modification to its leverage target is credit positive

Announcement: Moody's: HCA Healthcare's modification to its leverage target is credit positive. Global Credit Research- 03 Feb 2021. New York, February 03, 2021-- Moody's Investors Service commented that HCA Healthcare, Inc. and its related entities modification to its stated leverage target is credit positive because it indicates the company's willingness to commit to operating with somewhat more conservative financial leverage.

HCA Healthcare, Inc.: Modification to leverage target is credit positive

HCA's plan to operate with less financial leverage is credit positive, offset in part by very significant share repurchases and the reinstatement of the cash dividend.

HCA Healthcare, Inc.: Update to credit analysis

Our credit view of HCA Healthcare, reflecting its significant scale and strong free cash flow, tempered by pressures related to the ongoing pandemic and moderately high financial leverage.

HCA Healthcare, Inc. - September 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

HCA HEALTHCARE sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of HCA HEALTHCARE (US), a company active in the Health Care Providers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date May 4, 2021, the closing price was USD 206.34 and its potential was estimated at USD 226.52.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch